Navigation Links
Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project

Expansion of Genomic DNA from Multiple Cancer Populations Facilitates

Disease Studies

ANN ARBOR, Mich., Oct. 13 /PRNewswire/ -- Rubicon Genomics, Inc. today announced an agreement with SAIC-Frederick to amplify DNA samples for The Cancer Atlas Genome Project.

Rubicon Genomics was selected to amplify and standardize total genomic DNA from 3,000 tissue and blood samples from cancer patients. The Rubicon GenomePlex(TM) Whole Genome Amplification technology was judged best to amplify clinical DNA samples to the constant concentration and quality necessary for reproducible and accurate analysis using microarrays and PCR. The amplified DNA libraries will be deposited into the International Genomics Consortium Biospecimen Research Core as a renewable resource to be shared among international researchers to completely characterize the genomes of patients with three types of cancer. Their studies will help understand the causes of cancer, as well as how to detect and treat the diseases.

"This agreement is an important technical validation for GenomePlex," said Dr. John Langmore, vice-president of commercial development for Rubicon. "IGC-BRC collaborators were able to show that pre-amplification of patient DNA can increase the sensitivity, reproducibility and robustness of analysis of patient samples using major analytical instruments."

Rubicon provides custom GenomePlex services for major pharmaceutical, diagnostic and institutional customers in order to increase the clinical performance of genetic analysis instruments. GenomePlex kits are also available from Rubicon for diagnostic applications. GenomePlex not only makes analysis of routine frozen tissue more reproducible, but enables difficult clinical samples such as single cells, plasma, serum and formalin-fixed tissue to be analyzed by PCR, microarrays and next-gen sequencing. Furthermore, GenomePlex allows investigators and clinicians to test for multiple analytes from a single small sample, producing more information from clinical samples.

About Rubicon Genomics, Inc.

Rubicon, located in Ann Arbor, MI, is a pre-analytical platform company that has developed and commercialized reagents and kits to increase the analytical and clinical performances of DNA and RNA analysis platforms including Q-PCR, microarrays, and next-gen sequencing. Its GenomePlex(TM), TransPlex(TM), and MethylPlex(TM) products achieve unbiased amplification and standardization of total DNA, total RNA, and methylated DNA. By producing highly pure DNA of uniform concentration and molecular weight these products increase the sensitivity, specificity, and reproducibility of conventional instrumentation in research and diagnostic applications, including analysis of single cells, formalin-fixed tissue and plasma. Rubicon sells GenomePlex and TransPlex services to the research market, as well as licenses and kits to the clinical markets, including pre-implantation and prenatal testing, and diagnostic manufacturing. GenomePlex and TransPlex kits are sold to the research-only market by Sigma-Aldrich. In addition, Rubicon partners with diagnostic companies, using its pre-analytical MethylPlex platform to discover and validate new DNA methylation biomarkers, and to co-develop cancer diagnostic tests. For more information contact John Langmore, VP Commercial Development, at or (734) 368-1705.

About IGC

The International Genomics Consortium (IGC) is a non-profit medical research foundation established to expand upon the discoveries of the Human Genome Project and other systematic sequencing efforts by combining world- class genomic research, bioinformatics, and diagnostic technologies in the fight against cancer and other complex genetic diseases. IGC serves numerous common, unmet needs including: the standardization of the collection of properly consented tissues of interest, the molecular characterization of these tissues, and standardization in the representation of these results. IGC facilitates the transition of genomic discoveries to improve patient care and increase the speed in which new diagnostic, prognostic and predictive testing, and new drug and treatment regimens are developed. Founding support for IGC was provided by the City of Phoenix and from Maricopa County.

Contact: John Langmore

VP Commercial Development

(734) 368-1705

SOURCE Rubicon Genomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
2. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
3. Fralex provides update on timing of interim analysis results
4. Vanda Pharmaceuticals Provides Update on Iloperidone
5. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
6. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
7. New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer
8. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
9. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
10. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
11. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
Post Your Comments:
(Date:11/27/2015)... 2015 Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... Une nouvelle approche consistant à combiner l,immunothérapie au ...    Clinical Cancer Research . ...
(Date:11/27/2015)... , November 27, 2015 ... set to go online. The potential to save costs, ... vast and far from fully exploited as yet. Here, ... health records, either via mobile tablet or directly at ... --> ) -->      ...
(Date:11/27/2015)... Niederlande, November 27, 2015 ... bei fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special ... 10% off of their purchase of lice treatment product. In addition, customers will receive ... a company spokesperson. “Finding lice is a sure way to ruin the holidays, so ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community ... 30 (see Table 1-1 ). More than 3.7 billion people under the age ... type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . , ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices ... show that delves into an array of issues that are presently affecting Americans. Dedicated ... open dialogue, this show is changing the subjects consumers focus on, one episode at ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is ... Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College ... as only one of twelve colleges and universities in the state of California make ...
Breaking Medicine News(10 mins):